Theme: Innovations and Pharma Industry

World Biosimilars 2022

World Biosimilars 2022

Biosimilars 2023 is a phenomenal event which will be bringing together people from different domains of pharmaceutical and biopharmaceutical world such as Researchers, Analysts, Pharmacists, Pharmacovigilants,  Regulatory and IPR Attorneys, Business Development Teams, Professors, PhD research scholars and more to discuss on the topics related to Biosimilars. Biosimilars 2023 will be a great platform for exchanging new ideas and research. This gathering will provide networking sessions for Scientists, pharmacist, Biopharmaceuticals, Professors, Business Assistants, Students, and individuals from all bio similar & Pharmaceutical groups. It also helps in continuing education opportunities and quality information shared by Keynote Speakers, Symposia, hands-on workshops, and exhibition.


Biosimilars 2023 conveys recent developments in Pharma drug marketing and production of Pharma drugs and contract manufacturing. A complete knowledge of a scientific discipline that described the effects of Biosimilars drug marketing and Biosimilars Pharma now explores the Scope of Biosimilars drug marketing in industry & provides detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the generic drug market. The wider economic environment is also considered.



Track 1:Advanced Drug Delivery System


These potential new therapies differ from traditional small molecules and current large molecules. These are often targeted to cell surface targets or provided without a specific molecular targeting strategy. As a result, advanced drug delivery systems for targeted and controlled release of new molecules into tissues and cells are needed to optimize potential benefits to patients.  Our scientists are working to break down the barriers between our most promising new drug candidates and their tissue and cell targets. They are developing a wide range of nanoparticles * aimed at providing new modality to previously non-drug targets and precisely controlling their release in a patient-friendly and convenient formulation. They are also investigating innovative ways to obtain oral biopharmaceuticals through the intestinal wall. It has avoided drug developers for generations. Our biologists gain a better understanding of cell transport mechanisms, and chemists, mathematicians, and pharmaceutical scientists use these insights to optimize the design, properties, analysis, formulation, and delivery of  potential new drugs. increase. Together, they are developing next-generation drug delivery technologies, leading us to a course aimed at transforming the scientific advances that underpin our exciting new modality into the clinical interests of our patients.

Cancer vaccines

Human vaccines

HPV vaccines

Therapeutic  vaccination for autoimmune diseases

Novel vaccines

Clinical trials


Tracks 2: BCS and IVIVC Based Biowaivers

The term bioweber applies to the regulatory approval process when a document (application) is approved based on evidence of equivalence other than in vivo bioequivalence testing. For solid oral dosage forms, Bioweber is generally based on dissolution tests. • BCS is a scientific framework for classifying drug substances based on water solubility and intestinal permeability. In combination with drug lysis, BCS takes into account three major factors that determine the rate and extent of absorption of solid oral IR dosage forms: lysis, solubility, and intestinal permeability.

BCS bio waivers

Preclinical and clinical testing for oral drug delivery

Waiver for In vivo bioavailability or bioequivalence

Consideration of bio waiver extensions for BCS class III drugs

In vitro diffusion cells for dissolution testing in formulation development


Track 3: Biopharmaceutical Informatics

Biopharmaceutical informatics combines a knowledge-based informatics approach (database creation, curation, mining, etc.) with physics-based molecular modeling and simulation tools (derived from computational biophysics) for biopharmaceuticals. It is an interdisciplinary field that supports the development of. As with many new areas of science and technology, it is too early to provide an accurate definition of biopharmaceutical informatics. Biopharmacy informatics is a  computational task, either alone or in combination with experimental studies, aimed at facilitating efficient and cost-effective translation of biopharmacy candidates into drugs. This article describes calculations focused on predicting the site of chemical degradation of biopharmaceutical candidates. In particular, case studies will be used to discuss those involved in methionine oxidation, lysine saccharification, asparagine deamidation, and aspartic acid isomerization. However, computational modeling applications  extend to assessing other aspects of the feasibility of biological agents, such as the development of biological agents (see the various chapters of Kumar and Singh's Book 4). These techniques can  be extended to late  product development and lifecycle management of biopharmaceuticals already on the market. Business development is another potential application of biopharmacy informatics, enabling feasibility risk assessments to be integrated into the decision-making process for introducing biopharmaceutical candidates for development. Therefore, biopharmacy informatics can be applied organically  at all stages of biopharmaceutical discovery and development whenever knowledge of molecular properties is required.

  • Applications of computation in biologic drug development
  • Physics-based molecular modelling
  • Protein sequence-structural contexts and degradation reaction mechanisms
  • De risk biopharmaceutical development
  • Creation of databases and data mining
  • Pre-clinical immunogenicity risk assessment of bio therapeutics


Track 4:Biological Medicine

Biological medicines are used to treat many illnesses and symptoms and are the most advanced treatment available. Some biopharmaceuticals are used to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune diseases. Available biopharmacy revolutionizes cancer treatment, slowing or reversing the course of immune-related diseases, changing the lives of people with rare diseases, and previously effective for their condition It brought hope to many patients who  had no  treatment options. Biological agents that affect the immune system, such as adalimumab (Humira), can reduce the effectiveness of the vaccine. Live vaccines, including attenuated vaccines, should not be used while the patient is being treated with biologics that affect the immune system. Patients must complete all recommended immunizations before administering these types of dry biologics. Pre-screening for static tuberculosis (TB) is generally recommended.

  • Anatomy, Physiology, Pathology.
  • Microbiology, Cell Biology.
  • Toxicology, Pharmacology.
  • Epidemiology, Virology, Bacteriology, Immunology.
  • Biochemistry, Molecular Biology.
  • Phlebotomy.
  • Genetics, Embryology.


Track 5: Drug Formulation

Another important part of the formulation planning stage is determining what physical form the drug will take, whether solid, liquid or semi-solid. Since the ultimate purpose of a drug is to be taken by the patient to combat the disease, drug developers need to consider which dosage form will not disrupt the patient's life and schedule the most. Different doses have different patient intake plans. For example, do I need to take the medicine 3 times, 4 times, or only once a day? This is all important during the planning phase of the formulation. Given the dosage form, custom formulation developers such as Tedor Pharma need to consider the optimal form for manufacturing the drug. In the field of solid medicine, options such as capsules, coated tablets and sustained release tablets have become an issue. Then you can see the liquids that can make the medicine more delicious by adding sugar and other substances.

 In the field of parenteral medicine, you can focus on topical medicines such as creams, gels, eye drops, nasal drops and inhalers.

 As always, pre-formulation research helps developers  determine the form of the drug.

  • Oral drugs.
  • Parental Formulations
  • Topical Formulations
  • Modified release Formulations
  • Modified release Formulations
  • Modified release Formulations
  • Novel Drug Formulations


Track 6: Chemical and Analytical Strategies for Biosimilars

Small changes in these parameters can affect the various chemical sequences of a particular biosimilar, but in some situations the innovator may change the host cell, fermentation process, purification process, or even the manufacturing site. Possibly, the product can be verified without a complete new product development validation review, bio similar products are of reasonable and equivalent quality, safety, and efficacy as biological reference products. Is required by  regulators. The analytical techniques available to biosimilar manufacturers are extremely sophisticated, offering a variety of options for characterizing the product and comparing it to  the corresponding off-the-shelf reference product. This diverse analytical method can be used to examine the attributes of  biosimilar candidates and reference biologics, characterizing the attributes using the orthogonal method, facilitating rigorous structural characterization and physicochemical evaluation tests. And the characterization and strategic aspects


         Biosimilars multimodal techniques

         Biosimilars bio analytical methods

         Bioassays for comparability and potency testing

         LC/MS analysis for discovery, preclinical and clinical programs

         Biosimilars GMP protein analysis

         Biosimilars electrophoresis


Track 7: Encapsulated Drugs

Encapsulation is commonly used in drug delivery systems to protect a particular drug and form a shell that prevents it from leaching out before reaching the target site. The shell is usually composed of a hydrogel matrix or polymer nanostructures that can encapsulate the target drug. Of them, nanocapsules and nanospheres are the most common. Whereas vesicular nanocapsules typically immerse the drug in a liquid core surrounded by a solidified polymer shell, nanospheres are solid / bulk polymer matrices in which the drug is encapsulated within or on the structural surface.

                                     Member Variable Encapsulation

                                     Function Encapsulation

                                     Class Encapsulation

Track 8: Intellectual Property Rights

Intellectual property rights (IPRs) are defined as ideas, inventions, and creative expressions, based on which there is a public will to grant the status of property. IPR grants the inventor or creator of this property a specific exclusive right that allows them to derive commercial benefits from their creative efforts or reputation. There are various types of intellectual property protection such as patents, copyrights and trademarks. A patent is recognition of an invention that meets the criteria of global novelty, non-obviousness, and industrial applicability. IPR is a prerequisite for better identification, planning, commercialization, duplication and protection of inventions and creativity. Each industry needs to develop its own IPR policies, management styles, strategies, etc., depending on its area of ​​expertise. The pharmaceutical industry now has an evolving IPR strategy that requires a better focus and approach in the next era.

                           Artistic work. Literature. Music. Painting. Sculpture.

                           Computer program.

                           Indigenous intellectual property.

                           Internet domain name.



                           Service mark.

                          Trade secret.

Track 9: Pharmaceutical Chemistry

The design (drug design) and synthesis of physiologically active compounds is that the focus of pharmaceutical (medicinal) chemistry. The goal is to get new chemical molecules that may be accustomed find new pharmaceuticals or to boost existing drug structures, hence expanding the chemical medication portfolio. Although chemistry is very important, only experienced pharmaceutical chemists can work effectively in an exceedingly highly interdisciplinary environment and interact with scientists from other disciplines like biology, structural biology, pharmacology, chemistry, biochemistry, pharmacokinetics, pharmaceutical technology, toxicology, and translational medicine, among others.


  • Process Chemistry Considerations
  • Structure-activity relationships of drug Moiety
  • Synthetic chemistry including combinatorial methods
  • Invivo and in vitro bio transformation of drugs
  • Modelling and designing of small compounds



Track 10: Pharmaceutical Manufacturing

Pharmaceutical manufacture refers to the process of synthesising pharmaceutical medications on a large scale in the pharmaceutical industry. A succession of unit operations, such as milling, granulation, coating, tablet pressing, and others, can be broken down into the drug production process. The synthesis of the active component or medication (primary processing, or manufacture) and secondary processing, or the conversion of active pharmaceuticals into products appropriate for administration, are the two key processes of pharmaceutical manufacturing.

Trcak 11: Drug Delivery Technology

The distribution of drugs has the potential to revolutionise the treatment of retinal illnesses. There are many medications that are reasonably effective in treating retinal diseases, but their effectiveness is limited by delivery concerns such as the necessity for the molecule to pass the blood–eye barrier, stay present for long periods of time, or the need to minimise side effects. Drug delivery technology, whether it's cellular delivery systems, microelectromechanical (MEMs)-based devices, polymer matrices, or gene delivery systems, can solve the challenges of having drugs at a physiologically relevant concentration for extended periods of time or in a localised delivery system.

  • Nanoparticles.
  • Microchip technology.
  • Microneedle patches.
  • Ultrasound-guided delivery.


Track 12: Pharmacogenomics

The study of how genes influence a person's pharmacological reaction is known as pharmacogenomics. This field combines pharmacology (the science of pharmaceuticals) and genomics (the study of genes and their functions) to create effective, safe treatments depending on a person's genetic composition. Many current medications are "one size fits all," but they do not work in the same manner for everyone. It's difficult to know who will benefit from a medication, who won't, and who will have negative side effects (called adverse drug reactions). In the United States, adverse medication reactions are a leading cause of hospitalizations and deaths. Researchers are trying to figure out how genetic variations affect the body's response to drugs.

  • Food and Drug Administration.
  • Enzyme.
  • Drug Development.
  • Warfarin.
  • Biological Marker.
  • Adverse Event.
  • Toxicity.
  • Adverse Drug Reaction.


 Track 13: Consequences of Brexit on Biosimilars

In biosimilar replacement resulted in significant reductions in aggregate provider risk, implying that this possible intervention for providers to limit risk in VBP models for cancer care should be continued. Oncology biosimilars may play an important role in reducing provider risk in VBP models. The impact of bio similar substitution on provider risk is unknown, as previous research has primarily focused on the financial impact of generic adoption. Researchers modelled the quantitative technique of Medicare's OCM to quantify the impact of substitution on financial risk to providers in VBP models. Bevacizumab, rituximab, trastuzumab, epoetin alfa, filgrastim, and pegfilgrastim biosimilars were evaluated. Brexit- Pros and Cons to European pharma market

  • Post Brexit changes in biosimilars regulation in UK
  • Fate of biosimilars clinical trials in UK
  • Research funding from European organizations to UK based research laboratories


Track 14 : Digital Pharma

Implementing various digital technologies to enhance the creation and delivery of healthcare goods and services is known as "digital transformation" in the pharmaceutical industry. The following areas in the pharmaceutical industry can benefit from digital transformation: enhance the creation of drugs. One of the important factors in the pharmaceutical industry's profitability is the digitalization of control operations. Due to digitally automated control stages, there is a clear correlation between reduced usage of raw materials, labour, and time as well as decreased risk for low-quality end goods.

                                     Formulation manufacturers

                                     API manufacturers

                                     Contract manufacturing organizations (CMO)


To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 08-09, 2022
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed
Poster Opportunity Closed Click Here to View